Clofarabine Powder, Clofarabine Raw Material, Clofarabine CAS 123318-82-1

CAS: 123318-82-1

MF:  C10H11ClFN5O3

MW: 303.68

EINECS: 631-422-9

Specification​: 99% min Clofarabine

Sample:  Clofarabine Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Clofarabine Powder Usage and Synthesis.

Clofarabine Powder (Clofarabine) is a nucleotide analogue that combines the advantages of fludarabine and cladribine, inhibiting both DNA polymerase and ribonucleic acid reductase, Clofarabine Raw Material is currently the only suitable Clofarabine CAS 123318-82-1, also known as clofarabine, is a novel purine nucleoside anticancer drug, Clofarabine Powder is an antitumor drug that affects microtubule proteins, Clofarabine has an apoptotic Clofarabine Powder is an antitumor drug that affects microtubule proteins.

Clofarabine Powder inhibits both DNA polymerase and ribonucleic acid reductase and is currently the only drug suitable for the treatment of childhood leukemia, with a very high therapeutic efficacy rate of 31% in patients who did not respond to two conventional chemotherapy treatments; it is well tolerated by patients with no unpredictable adverse effects; and has potential broad-spectrum antitumor properties. Uses and functions of Clof

Uses and functions of Clofarabine Powder.

Clofarabine, also known as clofarabine, is a new purine nucleoside anticancer drug, clofarabine, which was approved by the U.S. Food and Drug Administration (FDA) on December 28, 2004 for the treatment of persistent or relapsing acute lymphoblastic leukemia in children through fast track, and is currently the only drug that can be used specifically for the treatment of acute childhood It is the only drug that can be used specifically for the treatment of childhood acute lymphoblastic leukemia (ALL); it is highly effective in the treatment of leukemia and is well tolerated without unpredictable adverse effects. It can be administered intravenously or orally and is the first new leukemia treatment approved specifically for children in more than a decade.

Clorabine is an antitumor drug that affects microtubulin and is used clinically to treat:

• ① relapsed or refractory drug-resistant acute lymphoblastic leukemia.
• ②It is effective in elderly patients with acute myeloid leukemia and myelodysplastic syndrome (MDS), and can be used in combination with cytarabine.

Regular adult dose:

• ① Relapsed refractory acute lymphoblastic leukemia: Patients (1 to 21 years of age) who have received at least 2 prior treatment regimens 52 mg/m2 daily x 5 days, IV (>2 hours), to be repeated every 2 to 6 weeks after recovery of organ function or return to baseline levels.
• ②Acute myeloid leukemia and MDS: 52 mg/m2 daily x 5 days, 1 hour IV; after 4 hours, give augmentin, 1 g/m2 daily x 5 days, 2 hours IV, which has a positive effect on elderly patients with newly diagnosed acute myeloid leukemia and high-risk MDS. Children: refractory relapsed acute gonorrhea, same dosage as adults.

Refractory relapsed acute non-lymphoblastic leukemia is treated with 52 mg/m2 daily x 5 days, IV (>2 hours), repeated every 2 to 6 weeks depending on toxicity and patient response.

Pharmacological Effects of Clofarabine Powder.

Clofarabine combines the advantages of fludarabine and cladribine, inhibiting both DNA polymerase and ribonucleic acid reductase; it has shown strong anticancer activity against different cell lines and tumor models.

Early studies have shown that concentrations below micromolar can effectively inhibit the proliferation of human CNS tumors, lung cancer, kidney cancer, leukemia cells and melanoma cell lines.In vivo and in vitro experiments have shown that clobazam has an apoptotic effect on leukemia cells, which is achieved by downregulating the BCL-2 family proteins BCL-X and MCL-1 and AKT dephosphorylation.

Its inhibitory effect on human leukemia cells K-562 was stronger than that of cladribine and fludarabine, with an IC50 of 5 nmol/L, compared to 16 nmol/L for cladribine and 460 nmol/L for fludarabine.

Preclinical and combined dosing trials have shown that clofarabine, like other deoxynucleotide analogs and other types of anticancer drugs such as etoposide, can increase the activity of deoxycytidine kinase in normal or abnormal human lymphocytes and therefore increase anticancer efficacy.